Blauvelt, A, RB Warren, K Reich, and et al. “Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated With Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine 3, no. 2 (March 11, 2019): 175. Accessed July 3, 2024. https://jofskin.org/33014/index.php/skin/article/view/532.